MedTrace Logo

Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer

NCT01081873 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2717

Last updated 2012-10-31

Study results available
· View outcomes & findings →

Summary

Document treatment patterns and evaluate LUCRIN / LUCRIN-TRIDEPOT® (Leuprolide) and alternative therapeutic approaches to the treatment of advanced prostate cancer during normal clinical practice and in accordance with the terms of the Belgian marketing authorization and reimbursement conditions.

Conditions

  • Prostatic Neoplasm

Interventions

DRUG

leuprolide (Lucrin/Lucrin-Tri-depot)

Subcutaneous or intramuscular administration for all participants

Sponsors & Collaborators

Principal Investigators

  • Simonne Lens · Abbott

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Belgium
  • Luxembourg

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01081873 on ClinicalTrials.gov